Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
Yijia Li, Linda J Harrison, Kara W Chew, Judy Currier, David A. Wohl, Eric S. Daar, Teresa H. Evering, Ryan Wu, Mark J Giganti, Justin Ritz, Arzhang Cyrus Javan, Robert W. Coombs, Carlee Moser, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Jonathan Z. Li
Abstract
Acute Coronavirus Disease 2019 symptoms limit daily activities, but little is known about its association with severe acute respiratory syndrome coronavirus 2 viral burden. In this exploratory analysis of placebo recipients in the ACTIV-2/A5401 platform trial, we showed that high anterior nasal RNA levels and detectable plasma RNA were associated with delayed symptom improvement. Clinical Trials Registration. https://clinicaltrials.gov/ct2/show/NCT04518410.
Topics & Concepts
MedicinePlaceboCoronavirusCoronavirus disease 2019 (COVID-19)Internal medicineClinical trialRespiratory diseaseRespiratory systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseBetacoronavirusImmunologyPathologyInfectious disease (medical specialty)LungAlternative medicineSARS-CoV-2 detection and testingLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research